Table 4.

Comparisons of major clinical staging between prednisolone and itraconazole in participants with severe asthma

	Total	Before trial		After one month		After 4 months
		Itraconazole	Prednisolone	Itraconazole	Prednisolone	Itraconazole
Cough
None	6 (6%)	2 (4%)	4 (10%)	14 (27%)	2 (10%)	13 (52%)
Mild	17 (17%)	9 (18%)	8 (16%)	8 (16%)	3 (15%)	8 (32%)
Moderate	19 (19%)	4 (8%)	15 (30%)*	6 (12%)	1 (5%)	2 (8%)
Severe	41 (41%)	30 (61%)	11 (22%)*	5 (10%)	3 (16%)	2 (8%)
Very severe	17 (17%)	6 (12%)	11 (22%)	1 (2%)	0 (0%)	0 (0%)
Mean	2.4±1.11	2.5±1.04‡	2.2±1.26	1.15±1.2‡	1.56±1.2¥	0.72±0.93‡
Dyspnea
None	2 (2%)	1 (2%)	1 (5%)	13 (38%)	5 (27%)	12 (48%)
Mild	3 (3%)	3 (6%)	0 (0%)	11 (32%)	2 (11%)	7 (28%)
Moderate	16 (16%)	5 (10%)	11 (23%)	4 (12%)	6 (33%)	4 (16%)
Severe	67 (68%)	31 (61%)	37 (72%)	6 (18%)	4 (22%)	1 (4%)
Very severe	11 (11%)	11 (21%)	0 (0%)	0 (0%)	1 (2%)	1 (4%)
Mean	2.8±0.83	2.9±0.85‡	2.6±0.76	1.09±1.11‡	2.1±1.26¥	0.88±0.21‡
Sputum
None	23 (23%)	7 (13%)	16 (32%)	35 (70%)	36 (75%)	40 (78%)‡
Translucent	2 (2%)	1 (2%)	1 (2%)	0 (0%)	0 (0%)	1 (2%)
White	30 (30%)	15 (30%)	15 (30%)	7 (13%)	8 (17%)	6 (12%)
Purulent	45 (45%)	28 (55%)	17 (36%)	9 (17%)	4 (8%)	4 (8%)
Sleep
All night	40 (41%)	12 (24%)	28 (58%)*	23 (70%)†	(50%)	44 (88%)
>3 d /week	19 (19%)	11 (23%)	8 (16%)	7 (21%)	0 (0%)	4 (8%)
< 3 d/week	28 (29%)	20 (41%)	8 (16%)	3 (9%)†	(50%)	0 (0%)
None/week	11 (11%)	6 (12%)	5 (10%)	0 (0%)	0 (0%)	2 (4%)
Mean	1.23±1.05	1.4±0.99*	0.78±1.06	0.39±0.65†‡	1.2±1.06	0.2±0.34‡
ACT	14.16±2.83	13.12±4.37	14.1±3.22	19.8±4.05†‡	14±5.62	20.9±4.9‡

* Significant difference between case and control group before the trial

†=Significant difference between case and control group after the treatment with Itraconazole

‡= Significant difference after the trial in the Itraconazole group (paired t test)

¥= Significant difference after the trial in the placebo group (paired t test)

ACT= Asthma control test